Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will delay further partnership discussions regarding R788 until after results from the Phase 2b clinical trials of R788 are available. The company expects that these results, involving approximately 650 additional patients, will substantially further the understanding of R788's potential and may therefore drive enhanced economics in a possible deal. The company expects to have a collaboration partnership in place prior to initiating Phase 3 clinical trials. Enrollment in the two Phase 2b clinical trials of R788, TASKi2 and TASKi3, are ahead of schedule and the results from these clinical trials are expected to be available in July and August 2009, respectively. In addition, analysis of the recently completed QT/QTc safety study has confirmed that R788 does not elicit a QT/QTc signal.

The company also announced that it has cut its research programs in virology and oncology as well as certain related development and administrative staff, which resulted in the dismissal of 36 employees or approximately 20% of the company's workforce. This measure is intended to maintain the company's emphasis on its active preclinical and clinical programs, while conserving the company resources. The company is still assessing the restructuring and other charges associated with this measure, which is expected to be predominantly recorded in the first quarter of 2009. As of December 31, 2008, the company had $134.5 million in cash, cash equivalents and available-for-sale securities, which the company believes is enough for it to maintain its current development priorities through the second quarter of 2010.

"We have decided that postponing the partnership for R788, pending the forthcoming clinical tri
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)...  The non-surgical Stretta® procedure employing ... is effective in control of gastroesophageal reflux disease ... medication 10 years post-procedure, according to an independent, ... Disease Week (DDW) meeting May 18-21, 2013 in ... "The sustained improvement in GERD-HRQL scores and ...
(Date:5/18/2013)... 18, 2013 The Open Paradigm Project, ... Occupy Psychiatry , and leading organizations in ... a social media campaign showcasing video testimonials by ... which focuses on pathology and illness rather than ... American Psychiatric Association,s (APA) rollout of its latest ...
(Date:5/17/2013)... -- The power of plants to cure and rejuvenate, ... depends on the plant kingdom, is the subject of ... Medicine: Healing Plants Around the World, Featuring ... 18 through September 8, 2013. (Photo:  ... attractions include a re-creation of the Western world,s oldest ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2
... Group, Inc. recently published its TreatmentTrends®: Renal Anemia ... based on survey results from ... interviews conducted with ten thought leaders in nephrology.  The ... and focuses specifically on the management of renal anemia ...
... Research Group (MRG), the global authority on medical ... US cardiac resynchronization therapy defibrillator market will be ... chronic resynchronization therapy defibrillators in New York Heart ... The New York Heart Association classification system ranks ...
Cached Medicine Technology:New Report by BioTrends Examines the Treatment of Renal Anemia in China 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3
(Date:5/20/2013)... Salt Lake Community College’s Know Greater Heroes program ... winners for 2013. As part of the award, the ... is a leadership training program that involves SLCC athletes who ... eat right, be active, and avoid drugs and alcohol. , ... program each year, and visit more than 30 schools each ...
(Date:5/20/2013)... May 20, 2013 Osborn’s Brain: ... to Anne G. Osborn’s 1993 award winning book Diagnostic ... the all-time bestselling neuroradiology texts. , In this ... touch to make complex topics visually appealing and easy ... brain imaging together with spectacular pathology examples, relevant anatomy, ...
(Date:5/20/2013)... 2013 Nearly 20 percent of kidneys that are ... for transplant due to factors ranging from scarring in ... the organ going too long without blood or oxygen. ... could be "recycled" to help solve the critical shortage ... Medical Center and colleagues, reporting in the journal ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... , Who:    Sloan Gibson, President, USO and ... President of Outreach Initiatives and Partners, ... Street , Representatives from:,              ...          • U.S. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... adult allogeneic stem cell manufacturing, research and development, ... of Medicine and Director of Interventional Cardiology Research ... join the Scientific and Medical Advisory Board for ... of Pennsylvania, Dr. Wilensky divides his time between ...
Breaking Medicine News(10 mins):Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Study suggests new source of kidneys for transplant 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 3
... Inc (Seattle WA) has agreed to pay the US ... illegal marketing// of the anti-cancer prescription drug Trisenox, the ... ,According to the government's complaint, CTI promoted the drug ... Food & Drug Administration (FDA). ,The alleged ...
... ladders can result in serious injury and affect people of ... injuries, yet receives little// , if any, instruction on ladder ... in the May issue of the American Journal of Preventive ... Policy (CIRP) at Columbus Children’s Hospital, more than 2.1 million ...
... in 1150AD said about Asthma – , ... in mind is a rational conduct of life//." ... chronic disease which affects almost 300 million worldwide remains the ... most commonly discussed respiratory disease after the common cold. The ...
... a new agent, called "Zorro-LNA," which has the potential ... study, researchers from the Karolinska// Institute in Stockholm, Sweden, ... strands of a gene’s DNA simultaneously, effectively disabling that ... for virtually every human condition caused by or worsened ...
... the rise among kids in the US, according to the largest government ... ,Sugary foods and drinks and nonfluoridated bottled water may be ... ,An estimated 28 percent of U.S. children ages 2 to 5 had ... This compared to a 24 percent rate from 1988 to 1994. ...
... cases of Polio reported globally are 111 out of which 31 ... number of polio cases reported// during the last three years, State ... circulation of wild polio virus following action are being taken: ... 2007 ,? One SNID implemented in UP, Bihar and ...
Cached Medicine News:Health News:CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG 2Health News:Ladder-related Injuries on the Rise in U.S 2Health News:Asthma can Be Checked, Experts are Confident 2Health News:Asthma can Be Checked, Experts are Confident 3Health News:Asthma can Be Checked, Experts are Confident 4Health News:New Agent to Fight Genetic Disorders Found 2Health News:Sugary Foods Turn Kids Teeth Rotten in US 2Health News:Polio Cases In The Country 2
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
DP 2020 Series 3-chip cameras offer the user unparalleled clarity and definition. Chroma dynamic range is extended and red colour reproduction is superb....
Medicine Products: